# A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

> **NCT07311694** · PHASE3 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 370 (estimated)

## Conditions studied

- PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer

## Interventions

- **DRUG:** HRS-4357 injection
- **DRUG:** Enzalutamide；Abiraterone

## Key facts

- **NCT ID:** NCT07311694
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 370 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07311694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07311694, "A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07311694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*